Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Preclinical

Preclinical (143 companies)

Companies with at least one active program at Preclinical.

Ticker Company Therapeutic areas Preclinical programs Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 2 Phase 3 $677M 5
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $25.6M 3
ABSI Absci DermatologyGI/Hepatology+1 3 Phase 1 $1.75B 6
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 $619M 8
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 1 Phase 2 $69.0M 9
ACTU Actuate Therapeutics Oncology 1 Phase 2 $7.9M 4
ABOS Acumen Pharmaceuticals Neurology 2 Phase 2 $16.2M 4
ADAG Adagene Oncology 3 Phase 2 $134M 10
ADCT ADC Therapeutics Oncology 1 Approved $202M 5
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $28.6M 8
ADMA Adma Biologics ImmunologyInfectious Disease Rare 1 Approved $2.82B 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 2 Phase 2 $376M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 2 Approved $111M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 1 NDA Submitted $38.3M 5
ATHE Alterity Therapeutics Neurology Rare 1 Phase 2 $46.4M 2
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.79B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 2 Phase 2 $151M 6
ANIX Anixa Biosciences Oncology 1 Phase 1 $111M 3
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 2 Phase 2 — 9
APVO Aptevo Therapeutics Oncology 6 Phase 1 $2.2M 8
RCUS Arcus Biosciences DermatologyImmunology+1 2 Phase 3 $2.63B 8
ARDX Ardelyx GI/HepatologyRenal 1 Approved $724M 4
ARVN Arvinas NeurologyOncology Rare 1 Approved $420M 10
ATAI Atai Beckley Neurology 2 Phase 2 $2.73B 5
AXSM Axsome Therapeutics Neurology Rare 2 Approved $6.96B 15
BLTE Belite Bio MetabolicOphthalmology Rare 4 NDA Submitted $6.21B 6
BCYC Bicycle Therapeutics Oncology 1 Phase 2 $253M 4
BMEA Biomea Fusion MetabolicOncology 1 Phase 2 $41.1M 4
BDTX Black Diamond Therapeutics Oncology 1 Phase 2 $99.7M 4
BCTX BriaCell Therapeutics Oncology 6 Phase 3 $34.5M 8
CADL Candel Therapeutics Oncology 1 Phase 3 $670M 4
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 $121M 4
CLRB Cellectar Biosciences Oncology 1 Phase 2 $11.8M 6
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 5 Phase 1 $304M 9
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $5.51B 7
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $889M 7
COYA Coya Therapeutics Neurology Rare 4 Phase 2 $70.1M 6
CBIO Crescent Biopharma Oncology 1 Phase 2 $503M 10
CUE Cue Biopharma ImmunologyOncology 3 Phase 2 $136M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 2 NDA Submitted $728M 10
CTMX CytomX Therapeutics Oncology 1 Phase 1 $477M 7
IRON Disc Medicine GI/HepatologyHematology+2 Rare 1 Phase 3 $3.59B 9
DYN Dyne Therapeutics MetabolicNeurology Rare 8 NDA Submitted $3.39B 10
EIKN Eikon Therapeutics Oncology 1 Phase 2 $320M 13
ELTX Elicio Therapeutics Oncology 3 Phase 2 $42.7M 6
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 1 Approved $320M 7
ENTX Entera Bio GI/HepatologyMetabolic Rare 2 Phase 2 $547M 4
ERAS Erasca Oncology 1 Phase 1 $5.04B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.63B 17
EVMN Evommune DermatologyImmunology+1 1 Phase 2 $241M 6
EXEL Exelixis CardiovascularOncology 3 Approved $17.0B 23
EYPT EyePoint Ophthalmology 1 Phase 3 $31.0M 2
FATE Fate Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $224M 10
FHTX Foghorn Therapeutics Oncology 3 Preclinical $111M 4
FBIO Fortress Biotech DermatologyHematology+3 Rare 1 Approved $61.7M 12
GANX Gain Therapeutics MetabolicNeurology Rare 4 Phase 1 $45.0M 5
HRMY Harmony Biosciences MetabolicNeurology Rare 6 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 2 Approved $1.01B 15
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $106M 4
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.60B 15
IMNM Immunome Oncology Rare 2 NDA Submitted $2.13B 9
INAB IN8bio ImmunologyOncology 1 Phase 1 $10.0M 4
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.24B 6
IVVD Invivyd Infectious Disease 2 Approved $166M 5
JBIO Jade Biosciences ImmunologyRenal Rare 2 Phase 2 $958M 4
KAPA Kairos Pharma Oncology 8 Phase 2 — 13
KZIA Kazia Therapeutics NeurologyOncology Rare 5 Phase 2 $82.0M 13
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $184M 5
KOD Kodiak Sciences Ophthalmology 2 Phase 3 $6.24B 8
KURA Kura Oncology MetabolicOncology 3 Approved $647M 12
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 1 Phase 2 $11.2B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $302M 7
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 7 Phase 2 $237M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 10 Phase 2 $258M 12
LGVN Longeveron CardiovascularMetabolic+1 Rare 1 Phase 2 $5.8M 4
MAIA MAIA Biotechnology Oncology 5 Phase 3 $64.5M 7
MPLT MapLight Therapeutics Neurology 3 Phase 2 $385M 6
MRKR Marker Therapeutics Oncology 1 Phase 1 $14.8M 4
MDNAF Medicenna Therapeutics Oncology 7 Phase 2 $29.5M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 7 Phase 3 $864M 16
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $52.8M 8
MBRX Moleculin Biotech Oncology 3 Phase 2 — 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $903M 7
NKTR Nektar Therapeutics DermatologyImmunology+2 4 Phase 3 $1.27B 11
NGEN NervGen Pharma Neurology 2 Phase 3 $143M 3
NRSN NeuroSense Therapeutics Neurology Rare 1 Phase 2 $3.2M 3
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $103M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.67B 13
OCGN Ocugen Infectious DiseaseOphthalmology Rare 3 Phase 3 $314M 12
OCS Oculis Holding NeurologyOphthalmology Rare 2 Phase 3 $417M 5
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.22B 6
OKUR OnKure Therapeutics Oncology 2 Preclinical $116M 2
IRD Opus Genetics Ophthalmology Rare 5 Approved $348M 12
ORIC Oric Pharmaceuticals Oncology 2 Phase 3 $914M 5
ORKA Oruka Therapeutics DermatologyImmunology Rare 1 Phase 2 $6.81B 7
OVID Ovid Therapeutics Neurology Rare 2 Phase 2 $557M 4
PTN Palatin Technologies ImmunologyMetabolic+1 Rare 2 Phase 3 $11.2M 8
PALI Palisade Bio Immunology 1 Phase 2 $197M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 $19.3M 4
PHIO Phio Pharmaceuticals Oncology 1 Phase 1 $9.6M 4
PYPD PolyPid Infectious DiseaseOncology 2 NDA Submitted $125M 3
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 1 Phase 1 $296M 5
PRLD Prelude Therapeutics HematologyOncology Rare 1 Phase 1 $287M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $5.4M 7
PMN ProMIS Neurosciences Neurology Rare 5 Phase 1 $37.3M 6
PRQR ProQR Therapeutics MetabolicNeurology Rare 3 Phase 1 $191M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 5 Approved $8.62B 12
QTTB Q32 Bio Dermatology 2 Phase 2 $277M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 2 Phase 2 $257M 4
RAPP Rapport Therapeutics Neurology 1 Phase 3 $1.45B 10
RXRX Recursion Pharmaceuticals Oncology 3 Phase 2 $2.19B 6
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $416M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+2 Rare 4 Phase 3 $4.8M 10
RVMD Revolution Medicines Oncology 3 Approved $41.6B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 1 Approved $7.78B 14
SANA Sana Biotechnology MetabolicOncology 3 Phase 1 $710M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 1 Approved $1.91B 11
SCYX Scynexis Infectious DiseaseRenal Rare 1 Approved $34.8M 5
SLS SELLAS Life Sciences Group Oncology 3 Phase 3 $1.70B 9
SEPN Septerna ImmunologyMetabolic+1 Rare 2 Phase 1 $2.28B 5
SLDB Solid Biosciences CardiovascularNeurology Rare 3 Phase 3 $736M 6
SPRB Spruce Biosciences Metabolic Rare 1 Preclinical $134M 2
SYRE Spyre Therapeutics DermatologyImmunology Rare 1 Phase 2 $9.86B 10
GPCR Structure Therapeutics MetabolicRespiratory Rare 1 Phase 3 $4.35B 5
STRO Sutro Biopharma Oncology 2 Phase 1 $160M 4
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 3 Approved $852M 7
TSHA Taysha Gene Therapies Neurology Rare 2 Phase 3 $1.41B 4
TLX Telix Pharmaceuticals Oncology 6 Approved $3.27B 25
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $87.8M 5
TVTX Travere Therapeutics MetabolicRenal Rare 2 Approved $4.76B 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 2 Phase 2 $282M 4
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 1 Approved $1.57B 10
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $231M 27
PCVX Vaxcyte Infectious Disease 2 Phase 3 $10.1B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 1 Approved $2.15B 6
VIR Vir Biotechnology Infectious DiseaseOncology Rare 1 Phase 3 $2.09B 12
VRDN Viridian Therapeutics ImmunologyOphthalmology 3 Approved $3.24B 7
VYGR Voyager Therapeutics MetabolicNeurology Rare 7 Phase 1 $116M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 2 Phase 3 $84.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $665M 5
XENE Xenon Pharmaceuticals Neurology Rare 1 NDA Submitted $3.79B 9
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 2 NDA Submitted $1.92B 11
ZYME Zymeworks OncologyRespiratory 3 Approved $2.10B 11